NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

Technology Appraisal (Committee D) meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 11 March 2021

**Location:** Via Zoom

# Committee members present

1. Professor Gary McVeigh [Chair] Present for all items
2. Dr Lindsay Smith [Vice Chair] Present for items 1 to 4.4.2
3. James Avery Present for all items
4. Martin Bradley Present for all items
5. Dr Matt Bradley Present for all items
6. Professor Sofia Dias Present for items 4 to 5.4.2
7. Professor Rachel Elliott Present for all items
8. Professor Paula Ghaneh Present for all items
9. Dr Rebecca Harmston Present for all items
10. Chris Herring Present for all items
11. Dr Andrew Hitchings Present for all items
12. Dr Robert Hodgson Present for all items
13. Dr Bernard Khoo Present for all items
14. Dr Soo Fon Lim Present for all items
15. Dr Guy Makin Present for all items
16. Professor David Meads Present for all items
17. Giles Monnickendam Present for all items
18. Malcolm Oswald Present for all items
19. Professor Chris Parker Present for all items
20. Baljit Singh Present for all items
21. Dr John Watkins Present for all items

# NICE staff present:

Linda Landells, Associate Director Present for items 1 to 3.4.2 & 5 to 5.4.2

Jasdeep Hayre, Associate Director Present for items 4 to 4.4.2

Kate Moore, Project Manager Present for items 1 to 3.4.2 & 5 to 5.4.2

Gavin Kenny, Project Manager Present for items 4 to 4.4.2

Caron Jones, Technical Adviser Present for items1 to 3.4.2 & 5 to 5.4.2

Christian Griffiths, Technical Adviser Present for items 4 to 4.4.2

Charlie Hewitt, Technical Analyst Present for items 1 to 3.4.2

Amy Crossley, Technical Analyst Present for items 4 to 4.4.2

Fatima Chunara, Technical Analyst Present for items 5 to 5.4.2

Maroulla Whiteley, Business Analyst, RIA Present for all items

Ann Greenwood, Medical Editor Present for items 1 to 3.4.2

Sarah Bromley, Medical Editor Present for items 4 to 4.4.2

Benjamin Pearce, Medical Editor Present for items 5 to 5.4.2

Ella Livingstone, Commercial Risk Assessment Team Present for items 1 to 3.4.2

Claire Hawksworth, Managed Access team Present for items 1 to 3.4.2 & 5 to 5.4.2

Thomas Strong, Managed Access team Present for all items

Stevie Okoro, Commercial Risk Assessment Team Present for items 4 to 5.4.2

Catherine Pank, Assistant Project Manager, COT Present for items 5 to 5.4.2

Mira Patel, Coordinator, COT Present for items 1 to 3.4.2 & 5 to 5.4.2

Gemma Smith, Coordinator, COT Present for all items

Rosalee Mason, Coordinator, MIP Present for items 4 to 4.3

Victoria Hall, Coordinator, MIP Present for items 4 to 4.3

Ismahan Abdullah, Administrator, TA Present for items 4 to 4.4.2

Celia Mayers, Administrator, TA Present for items 1 to 3.4.2 & 5 to 5.4.2

Heidi Livingstone, Public Involvement Adviser Present for items 1 to 3.3

Laura Marsden, Public Involvement Adviser Present for items 4 to 4.3

Daniel Greenwood, Assistant Administrator, COT Present for items 4 to 4.4.2

# External group representatives present:

Peter Murphy, NHS Centre for Reviews and Dissemination and Centre for Health Economics Present for items 1 to 3.3

Sahar Sharif, NHS Centre for Reviews and Dissemination and Centre for Health Economics Present for items 1 to 3.3

Anthony Hatswell, Peninsula Technology Assessment Group, University of Exeter, Present for items 4 to 4.3

Caroline Farmer, Peninsula Technology Assessment Group, University of Exeter, Present for items 4 to 4.3

Lorna Aucott, Aberdeen HTA Group Present for items 5 to 5.3

Andrew Walker, Aberdeen HTA Group Present for items 5 to 5.3

# Professional experts present:

Dr Alastair Greystoke, Consultant Medical Oncologist, Newcastle Freeman Hospital Present for items 1 to 3.3

Professor Mary O’Brien, Consultant Medical Oncologist, NCRI lung CSG, Present for items #1 to 3.3

Peter Barton, Macmillan Lung Cancer Specialist Nurse, Lung Cancer Nursing UK , Present for items 1 to 3.3

Peter Clark, CDF Clinical Lead, NHS England, Present for items 1 to 3.4.2 & 5 to 5.4.2

Dr Sunil Daga, Consultant Nephrologist, Leeds Teaching Hospital NHS Trust, Present for items 4 to 4.3

Dr Colin Geddes, Consultant Nephrologist and Honorary Clinical Associate Professor, NHS Greater Glasgow, and Clyde, Present for items 4 to 4.3

Dr Richard Baker Clinical expert. NHS blood and transplant, Present for items 4 to 4.3

Dr Nicholas Torpey Consultant Nephrologist, Addenbrooke’s Hospital, Cambridge and Treasurer, British Transplantation Society [BTS], Present for items 4 to 4.3

Richard Ayres Patient expert nominated by Kidney Care UK, Present for items 4 to 4.3

Dr Yvonne Summers Consultant Medical Oncologist & Honorary Senior Lecturer, Manchester University NHS Foundation Trust, Present for items 5 to 5.3

1. Introduction to the meeting
   1. The chair welcomed members of the committee and other attendees present to the meeting.
2. News and announcements
   1. None.
3. Appraisal of Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]
   1. Part 1 – Open session
      1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from BMS
      2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Professor David Meads declared a non-financial interest as the University of Leeds has received funding from Celgene and Bristol-Myers Squibb for research in an unrelated area.
* It was agreed that his declaration would not prevent David from participating in this section of the meeting.
* Dr Alastair Greystoke declared a financial interest as he has previously received consultancy and speaker fees from BMS.
* It was agreed that his declaration would not prevent Alastair from providing expert advice to the committee.
* Professor Mary O’Brien declared a financial interest as she has taken part in advisory boards for the competitors MSD and Roche.
* It was agreed that her declaration would not prevent Mary from providing expert advice to the committee.
* Committee member Sofia Dias is also part of the York ERG team who carried out the assessment for this appraisal and therefore as a direct conflict Sofia did not attend the meeting for this topic.
* No further conflicts of interest were declared for this appraisal.
  1. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
  2. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
  3. Part 2 – Closed session [company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting]
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD]. The committee decision was reached by consensus..
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD] in line with their decisions.

1. Appraisal of Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease [ID1672]
   1. Part 1 – Open session
      1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Hansa.
      2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Dr Sunil Daga declared a non-financial interest as he Is an investigator in a clinical trial that is looking at effectiveness of another desensitisation treatment funded by Kidney Research UK [ITOPS]. He also holds an honorary position as scientific advisor to Kidney Research Yorkshire, medical advisor to South Asian Health Action charity and honorary secretary at British Association of Physicians of Indian Origin [BAPIO] Institute for Health Research and has published opinion on antibody incompatible kidney transplantation.
* It was agreed that his declaration would not prevent Sunil from providing expert advice to the committee.
* Dr Colin Geddes declared a financial interest as he has unrestricted research grant funding from Retrophin Inc 2018 to his institution.
* It was agreed that his declaration would not prevent Colin from providing expert advice to the committee.
* Dr Nicholas Torpey declared a financial Interest as he has participated in advisory boards and been paid to give lectures in sponsored symposia by several pharmaceutical companies, including Hansa Biopharma and Astellas. Nicholas confirmed he does not have any direct financial interest in any pharmaceutical company.
* It was agreed that his declaration would not prevent Nicholas from providing expert advice to the committee.
* Richard Baker declared a financial Interest as he was paid an honorarium by Hansa for attending a virtual AD board on June 11, 2020.
* It was agreed that his declaration would not prevent Richard from providing expert advice to the committee.
* No further conflicts of interest were declared for this appraisal.
  1. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
  2. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
  3. Part 2 – Closed session [company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting].
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD]. The committee decision was reached by consensus..
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD] in line with their decisions.

1. Appraisal of Atezolizumab monotherapy for untreated PD-L1 positive metastatic non-small-cell lung cancer [ID1678]

The Committee for Medicinal Products for Human Use [at the European Medicines Agency] has not yet given its regulatory opinion for this technology and as a consequence the discussion on this topic took place in a part 2 session only [part 2 sessions are closed to public observers].

* 1. Part 2a – Closed session
     1. The chair welcomed the invited professional experts, external group representatives, and company representatives from Roche.
     2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Professor David Meads declared a non-financial interest as the University of Leeds has received funding from Roche, Celgene, and Sanofi for research in an unrelated area.
* It was agreed that his declaration would not prevent David from participating in this section of the meeting.
* Dr Yvonne Summers declared a financial interest as she has participated in advisory boards for NSCLC with; Roche, Takeda, Pfizer, AstraZeneca, BMS, Lily & Amgen.
* It was agreed that her declaration would not prevent Yvonne from providing expert advice to the committee.
* No further conflicts of interest were declared for this appraisal.
  1. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment
  2. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
  3. Part 2b – Closed session [company representatives, professional experts and external group representatives were asked to leave the meeting]
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD]. The committee decision was reached by consensus..
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination [FAD] in line with their decisions.

1. Date of the next meeting

The next meeting of the Technology Appraisal (Committee D) will be held on Wednesday 14 April 2021 and will start promptly at 09.30am.